Abstract
Corticobasal degeneration (CBD) is a complex neurodegenerative disorder which nomenclature of which its nomenclature and characterization continues to evolve. The core clinical features that have been considered characteristic of the disorder include progressive asymmetric rigidity and apraxia, with other findings suggesting additional cortical (e.g., alien limb phenomena, cortical sensory loss, myoclonus, and mirror movements) and basal ganglionic (e.g., bradykinesia, dystonia, and tremor) dysfunctions. The characteristic findings at autopsy are asymmetric cortical atrophy that is typically maximal in the frontoparietal regions, as well as basal ganglia and nigral degeneration. Microscopically, abnormal accumulations of the microtubule-associated tau protein are found in both neurons and glia, and this disorder is now considered one of the “tauopathies.” CBD was initially thought to represent a distinct clinicopathologic entity. Recent studies have shown considerable clinicopathologic heterogeneity, leading some to use the term “corticobasal syndrome” (CBS) for the constellation of findings initially considered characteristic of the disorder, and the term “corticobasal degeneration” for the histopathologic disorder. In this review, the multiple phenotypes/syndromes associated with CBD pathology, and multiple diseases associated with the CBS, are presented. The clinicopathologic heterogeneity in CBS/CBD and the implications of this heterogeneity on clinical practice, on understanding the focal/asymmetric cerebral degeneration syndromes, and on future research are all reviewed.
Similar content being viewed by others
References
Boeve B (2005) Corticobasal degeneration: the syndrome and the disease. In: Litvan I (ed) Atypical parkinsonian disorders. Humana, Totawa, pp 309–334
Boeve B (2007) Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis. Alzheimer Dis Assoc Disord 21:S31–S38
Boeve BF, Maraganore DM, Parisi JE et al (1999) Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53:795–800
Boeve B, Lang A, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54:S15–S19
Caselli R, Jack C (1992) Asymmetric cortical degeneration syndromes: a proposed clinical classification. Arch Neurol 49:770–780
Caselli R, Jack C, Petersen R (1992) Asymmetric cortical degeneration syndrome: clinical and radiologic correlations. Neurology 42:1462–1468
Dickson D, Bergeron C, Chin S et al (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:935–946
Gibb W, Luthert P, Marsden C (1989) Corticobasal degeneration. Brain 112:1171–1192
Gibb W, Luthert P, Marsden C (1990) Clinical and pathologic features of corticobasal degeneration. In: Streifler M, Korczyn A, Melamed E, Youdim M (eds) Advances in neurology: Parkinson’s disease: anatomy, pathology, and therapy. Raven, New York, pp 51–54
Hassan A, Whitwell J, Boeve B et al (2010) Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 16:208–214
Josephs K, Duffy J, Strand E et al (2006a) Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 129:1385–1398
Josephs KA, Petersen RC, Knopman DS et al (2006b) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66:41–48
Kertesz A (2003) Pick’s complex and FTDP-17. Mov Disord 18:S57–S62
Kertesz A, Munoz D (2000) Diagnostic controversies: is CBD part of the “Pick complex”? Adv Neurol 82:223–231
Kertesz A, Munoz D, Hillis A (2003) Preferred terminology. Ann Neurol 54:S3–S6
Kouri N, Whitwell J, Josephs K, Rademakers R, Dickson D (2011) Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 7:263–272
Lerner A, Friedland R, Riley D et al (1992) Dementia with pathological findings of cortical–basal ganglionic degeneration. Ann Neurol 32:271
Ling H, O’Sullivan S, Holton J et al (2010) Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133:2045–2057
Rebeiz J, Kolodny E, Richardson E (1967) Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 92:23–26
Rebeiz J, Kolodny E, Richardson E (1968) Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18:20–33
Rohrer J, Beck J, Warren J et al (2009) Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation. J Neurol Neurosurg Psychiatry 80:1297–1298
Rossi G, Marelli C, Farina L et al (2008) The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Mov Disord 23:892–895
Schneider J, Watts R, Gearing M, Brewer R, Mirra S (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48:959–969
Tang-Wai D, Graff-Radford N, Boeve B et al (2004) Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 63:1168–1174
Tartaglia M, Sidhu M, Laluz V et al (2010) Sporadic corticobasal syndrome due to FTLD-TDP. Acta Neuropathol 119:365–374
Acknowledgements
This study was supported by grants AG06786 and AG16574 from the National Institute on Aging. The author thanks his many colleagues for their ongoing support and collaborations in CBS/CBD research, and particularly extends his appreciation to the patients and their families for participating in research on CBS/CBD.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boeve, B.F. The Multiple Phenotypes of Corticobasal Syndrome and Corticobasal Degeneration: Implications for Further Study. J Mol Neurosci 45, 350–353 (2011). https://doi.org/10.1007/s12031-011-9624-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-011-9624-1